Tatva Chintan Pharma Q4 Results: Profit Falls 43%
Tatva Chintan Pharma Chem Ltd.'s consolidated net profit declined 43% in the fourth quarter of financial year 2024.
The specialty chemical manufacturer's profit declined to Rs 9.6 crore in the quarter-ended March, according to an exchange filing on Friday. Analysts tracked by Bloomberg had a consensus estimate of Rs 6.82 crore.
Tatva Chintan Pharma Chem Q4 Highlights (Consolidated, YoY)
Revenue down 21% at Rs 98.2 crore vs Rs 124.5 crore (Bloomberg estimate: Rs 97.3 crore).
Ebitda down 3.7% at Rs 15.6 crore vs 16.2 crore (Bloomberg estimate: Rs 15.18 crore).
Ebitda margin at 15.8% vs 13% (Bloomberg estimate: 15.6%).
Net profit down 43% at Rs 9.6 crore vs Rs 16.9 crore (Bloomberg estimate: Rs 6.82 crore).
During the quarter, the business volume have shown improvement. "We anticipate to continue a moderate growth over the next two quarters, with an uptick expected in Q3/Q4 FY25," said Chintan Shah, managing director of Tatva Chintan Pharma Chem.
The improvement in business sentiment is evident, with a notable increase in inquiries, shift in customer behaviour along with improved volume, he added.
Shares of Tatva Chintan Pharma Chem closed 1.62% higher at Rs 1,248 apiece on the NSE, as compared with a 0.76% decline in the benchmark Nifty 50 on Friday.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.